-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

Benzinga·05/20/2026 13:50:25
Listen to the news
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.